Structure Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $80 price target Structure’s focus on oral obesity medicines, particularly the lead asset GSBR-1290, is the future of long-term obesity therapy, allowing physicians to easily titrate doses, plan for intermittent dosing especially in cases like pregnancy, and allow optimization of treatment algorithm, once the required weight loss has been achieved, the analyst tells investors in a research note. The firm thinks the early data from 12-week GSBR-1290 “is impressive.”